Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.

被引：1

作者：

Fisher, George A.

Pommier, Rodney F.

Wolin, Edward M.

Kunz, Pamela L.

Liyanage, Nilani

Lowenthal, Susan W. Pitman

Mirakhur, Beloo

Shaheen, Montaser F.

Vinik, Aaron

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] Oregon Hlth & Sci Univ, Div Surg Oncol, Portland, OR 97201 USA

[3] Univ Kentucky, Lexington, KY USA

[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[5] Ipsen Innovat, Les Ulis, France

[6] Ipsen, Basking Ridge, NJ USA

[7] Univ New Mexico, Comprehensive Canc Ctr, Albuquerque, NM 87131 USA

[8] Eastern Virginia Med Sch, Norfolk, VA 23501 USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.4088

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4088

引用

页数：5